• 11q13.3q13.4 deletion plus 9q21.13q21.33 duplication in an affected girl arising from a familial four-way balanced chromosomal translocation
• 11q23/MLL rearrangements in adult acute leukemia
• A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib
• A Cryptic t(11;14) Translocation in Mantle Cell Lymphoma Highlights the Importance of FISH
• A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas
• A genomic case study of desmoplastic small round cell tumor: comprehensive analysis reveals insights into potential therapeutic targets and development of a monitoring tool for a rare and aggressive disease
• A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation
• A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome
• A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera
• Acquisition of a t(11;14)(q13;q32) in clonal evolution in a follicular lymphoma with a t(14;18)(q32;q21) and t(3;22)(q27;q11.2)
• Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not <em>MLL</em> gene
• Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes
• Advances in the assessment of minimal residual disease in mantle cell lymphoma
• Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature
• Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis
• An Original Complex Rearrangement Involving Chromosomes 9, 11, and 14, Harboring a Complex KMT2A Gene Rearrangement in an Infant With Mixed-phenotype Acute Leukemia
• Application of multiple MLL gene rearrangement detection techniques for children with acute mononuclear leukemia
• Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain
• Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells
• Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event
• Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review
• Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
• Clinical significance of detecting t(11;14) by fluorescence in situ hybridization for the diagnosis of 7 patients with atypical mantle cell lymphoma
• Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemia: A case report
• Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
• Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo Acute Myeloid Leukemia with t(11;20)(p15;q12) and t(2;5)(q33;q31)
• Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
• Confirmation of a maternal cryptal balanced translocation through analysis of a fetus using microarray
• Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials
• Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report
• Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5
• Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
• Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials
• Distal Deletion of Chromosome 11q Encompassing Jacobsen Syndrome without Platelet Abnormality
• Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
• Fibroma of tendon sheath with 11q rearrangements
• First Case of Double T-Cell Receptor Alpha/Delta Rearrangements of t(11;14) and inv(14) and Subsequent <em>JAK2</em> Rearrangement in a Patient With T-cell Acute Lymphoblastic Leukemia
• First Case of Double T-Cell Receptor Alpha/Delta Rearrangements of t(11;14) and inv(14) and Subsequent JAK2 Rearrangement in a Patient With T-cell Acute Lymphoblastic Leukemia
• Histologic transformation of t(11;18)-positive MALT lymphoma presented with aberrant T-cell marker expression
• Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma
• IGF2BP1: a novel IGH translocation partner in B acute lymphoblastic leukemia
• IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients
• Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms
• Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis
• Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma
• Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma
• Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma
• Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
• Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele
• Management of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the <em>MALT1</em> gene
• Mantle cell lymphoma concurrent with T-large granular lymphocytic leukemia: report of a case and review of literature
• Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation
• Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years
• miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11
• Mortality and cancer incidence in carriers of constitutional t(11;22)(q23;q11) translocations: A prospective study
• MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR
• Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results
• Multiple myeloma with t (8;14) and t (11;14) and extramedullary infiltration of multiple organs
• Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence
• Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia
• MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes
• Natural history of multiple myeloma patients refractory to venetoclax: A single center experience
• Neoplastic plasma cells mimic mature neutrophils in plasma cell myeloma with t(11;14)(q13;q32)
• New euchromatic variant dup(11)(p15.3p15.1) transmitted through two generations defined by low coverage whole genome sequencing
• One translocation for 2 lymphoid neoplasms
• Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/<em>KMT2A</em> Rearrangements in a Modern Therapy Era: A Retrospective International Study
• Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy
• PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32)
• Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
• Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
• Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen
• Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma
• PX-RICS-deficient mice mimic autism spectrum disorder in Jacobsen syndrome through impaired GABAA receptor trafficking
• Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma
• Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations
• Secondary plasma cell leukaemia treated with single agent venetoclax
• Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)
• Skin Involvement of Mantle Cell Lymphoma May Mimic Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type
• SOX11 as a minimal residual disease marker for Mantle cell lymphoma
• SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement
• t(11;14) status is stable between diagnosis and relapse and concordant between detection methodologies based on fluorescence in situ hybridization and next-generation sequencing in patients with multiple myeloma
• t(11;14)-positive mantle cell lymphomas lacking cyclin D1 (CCND1) immunostaining because of a CCND1 mutation or exclusive expression of the CCND1b isoform
• Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
• The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
• The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma
• The t(11;14)(q13;q32)/CCND1-IGH translocation is a recurrent secondary genetic aberration in relapsed chronic lymphocytic leukemia
• Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
• Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
• Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens
• Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities
• Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
• Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review
• Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)
• Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone
• Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?
• Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort
• Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)
• Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
• Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma
• What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?